Nakayama, Izuma
Qi, Changsong
Chen, Yang
Nakamura, Yoshiaki http://orcid.org/0000-0002-5241-6855
Shen, Lin http://orcid.org/0000-0003-1134-2922
Shitara, Kohei http://orcid.org/0000-0001-5196-3630
Article History
Accepted: 20 February 2024
First Online: 19 March 2024
Competing interests
: Y.N. has acted as consultant and/or adviser of Daiichi Sankyo, Exact Sciences Corporation, Gilead Sciences, Guardant Health, Natera, Premo Partners, Roche, Seagen, Takeda Pharmaceutical and has acted as a speaker for Becton Dickinson and Company, CareNet, Chugai Pharmaceutical, Daiichi Sankyo, Eisai, Guardant Health, Genomedia, Hisamitsu, Merck, Miyarisan, MSD, Roche Diagnostics, Seagen, Taiho Pharmaceutical, Tempus Labs, Zeria Pharmaceutical. K.S. has acted as a consultant and/or adviser of ALX Oncology, Inc., Amgen, Astellas, AstraZeneca, Bayer, Boehringer Ingelheim, Bristol Myers Squibb, Daiichi Sankyo, Guardant Health Japan, Janssen, Merck Pharmaceutical, Novartis, Ono Pharmaceutical, Takeda, Zymeworks Biopharmaceuticals and has received (institutional) research funding from Astellas, Amgen, Chugai, Daiichi Sankyo, Eisai, Merck Pharmaceutical, Ono Pharmaceutical, PRA Health Sciences, Syneos Health and Taiho Pharmaceutical. The other authors declare no competing interests.